Resources

Why do CDMO’s in Europe, Asia and the US look to Australia for early stage…

Ryan HardingFebruary 27, 2026

News

Melbourne, Australia The first clinical dose of PMCC-COE19, developed by Peter Mac and manufactured by…

Ryan HardingFebruary 20, 2026

News

Melbourne, Australia Our client Arovella Therapeutics Ltd (ASX: ALA) recently announced that the U.S. Food…

Ryan HardingFebruary 18, 2026

News

Cell Therapies CEO Bev Menner and ACTRIS Executive Director, A/Prof Aloysius Ho, at Cell Therapies'…

Ryan HardingFebruary 11, 2026

News

Cell Therapies CEO Bev Menner and ENCell Director, CDMO Business Development Gonson Yeom at Cell…

Ryan HardingDecember 5, 2025

Ryan Harding

Unrivalled experience and service from a global leader in cell and gene therapy manufacturing